When Wegovy Stops Working at 2.4mg: A Practical Guide

Step 1: Understand why the plateau is happening

The most common misconception here is worth letting go of gently: a plateau doesn't mean Wegovy has "stopped working" in any absolute sense. What it usually means is that your body has reached a new equilibrium. Semaglutide reduces appetite by mimicking the GLP-1 hormone, slowing gastric emptying and signalling fullness to the brain. Over months, your calorie intake falls and so does your metabolic rate — the body defends its current weight. The medicine is still doing its job; the biological resistance has caught up with it.

Clinical trial data from the STEP programme, published in the New England Journal of Medicine, showed that average weight loss levelled off well before the 68-week endpoint for many participants. A plateau after six to twelve months at 2.4mg is therefore not unusual. The question is whether it represents the ceiling of your response to this dose, or a temporary stall that lifestyle adjustments can shift. Your prescriber is the right person to make that call, because the answer differs from person to person.

Before concluding that the dose isn't doing enough at 2.4mg, it's worth reviewing a few basics: protein intake (low protein accelerates muscle loss and slows metabolism), sleep quality, stress levels and whether activity has quietly decreased as appetite fell. None of these replace a clinical conversation, but they matter to the answer.

Step 2: Know when a dose increase is the appropriate route

If a genuine plateau persists after ruling out lifestyle factors, the most significant development for people in this position is the MHRA's April 2026 approval of the dedicated 7.2mg Wegovy pen, a single weekly injection at more than three times the previous maximum dose. Early trial data reported average weight loss of around 20.7% over 72 weeks at 7.2mg, which is substantially higher than the 2.4mg figures. This dose is licensed for adults with a BMI of 30 or above and is reached by titrating through the existing schedule; no one moves directly to 7.2mg from 2.4mg without the intermediate steps.

A prescriber reviewing your case will weigh up how long you've been at 2.4mg, your current weight and BMI, any side effects you've experienced, and whether the plateau has lasted long enough to warrant escalation rather than watchful waiting. If you're on a private programme, that review can happen quickly. A question our prescribers hear regularly is whether requesting a higher dose means starting again, it doesn't; it means adjusting the plan you're already on.

It's also worth being clear about what a dose increase isn't: it isn't a guarantee of renewed loss. Some people reach a biological plateau that higher doses shift; others need a different approach entirely. That distinction is exactly what a clinical assessment is for. For a broader look at how the Wegovy dose schedule works from the start, the Wegovy doses guide sets out each step in plain terms.

Step 3: Consider whether 2.4mg was always the end point for you

NICE's guidance on semaglutide (TA875) recommends that treatment is reviewed if a patient achieves less than 5% weight loss after six months on the maintenance dose, with a clinical conversation about whether continuing makes sense. That threshold is a floor, not a ceiling: some people lose well beyond it, some fall short, and the same person's response can shift over time. If you've stopped losing weight on Wegovy 2.4mg after a period of good progress, the clinical picture looks very different from someone who never responded at all.

People who transferred to Wegovy from another GLP-1 medicine, or who have been on 2.4mg for over a year, sometimes find that their prescriber recommends a structured break or a switch rather than escalation. That's a legitimate pathway too, and not one to dismiss. The NHS's semaglutide information page outlines the general principles; your prescriber applies them to your specific situation.

Cost is a practical reality here as well. Moving to a higher dose affects how much treatment costs each month, and it's reasonable to factor that in. The Wegovy pricing page gives current context, though specific figures are always confirmed at consultation. At lower doses (say, if you're wondering whether issues started earlier) the patterns at 1mg or 1.7mg sometimes illuminate what's happening now at 2.4mg, particularly if the plateau began before you reached the maximum dose.

Step 4: Get a proper clinical review before making any changes

Self-adjusting a Wegovy dose (skipping a pen, doubling up, or stopping abruptly) isn't the right move, and can make the situation harder to manage. Stopping semaglutide abruptly is associated with weight regain; unsupervised dose increases carry a higher risk of gastrointestinal side effects. The right step is a clinical review that looks at your full picture: weight trajectory, dose history, any symptoms, and your goals.

If you're on a private programme and feel your current provider isn't reviewing your progress regularly, that's a service problem as much as a clinical one. Aftercare and dose-review support should be included in what you're paying for, not an optional extra. Our clinical team reviews every repeat prescription before it's issued, including whether the current dose remains appropriate. If you're at a point where you'd like a fresh clinical assessment, checking your eligibility is the place to start.